WAM
TVTX icon

Wolverine Asset Management’s Travere Therapeutics TVTX Stock Holding History

Wolverine Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-14,661
Closed -$242K – 1625
2019
Q2 		$294K Buy
+14,661
New +$289K ﹤0.01% 969

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Asset Management's TVTX Position: Q3 2019 in Review

Wolverine Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2019, closing a stake of 14,661 shares — an estimated $242K sold.

Wolverine Asset Management first reported a position in TVTX in Q2 2019 and held it in 1 quarter. The position peaked at $294K in Q2 2019. 130 funds tracked by Wall St. Rank hold TVTX as of Q3 2019.

  • Wolverine Asset Management reported no remaining Travere Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Wolverine Asset Management sold 14,661 Travere Therapeutics shares in Q3 2019, an estimated $242K.
  • Wolverine Asset Management first reported a position in Travere Therapeutics in Q2 2019 and held it in 1 quarter.
  • Wolverine Asset Management's Travere Therapeutics position peaked at $294K in Q2 2019.
  • 130 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2019.

Based on Wolverine Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.